Ascend Wellness Holdings (AAWH) Non-Current Deferred Tax Liability (2020 - 2026)
Ascend Wellness Holdings' (AAWH) quarterly Non-Current Deferred Tax Liability came in at $20.2 million in Q1 2026, down 14.17% year-on-year from $23.5 million in Q1 2025, and down 6.15% quarter-over-quarter from $21.5 million in Q4 2025.
Ascend Wellness Holdings (AAWH) Non-Current Deferred Tax Liability (2020 - 2026) Analysis & Trends
Ascend Wellness Holdings' Non-Current Deferred Tax Liability history runs 7 years deep, the most recent figure standing at $20.2 million for Q1 2026.
- On a quarterly basis, Non-Current Deferred Tax Liability fell 14.17% year-over-year to $20.2 million in Q1 2026; TTM through Mar 2026 was $20.2 million, a 14.17% decrease from a year earlier, with the FY2025 full-year figure at $21.5 million, down 8.21% from the prior year.
- Non-Current Deferred Tax Liability eased to $20.2 million in Q1 2026 per AAWH's latest filing, from $21.5 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $110.6 million in Q4 2023 and bottomed at $276000.0 in Q1 2022.
- The 5-year median for Non-Current Deferred Tax Liability is $25.6 million (2024), against an average of $30.8 million.
- Across the five-year window, Non-Current Deferred Tax Liability surged 11292.03% in 2023 and tumbled 78.81% in 2024, its largest moves.
- Year by year, Non-Current Deferred Tax Liability stood at $33.6 million in 2022, then jumped by 229.18% to $110.6 million in 2023, then tumbled by 78.81% to $23.4 million in 2024, then slipped by 8.21% to $21.5 million in 2025, then slipped by 6.15% to $20.2 million in 2026.
- Per Business Quant, the three latest AAWH Non-Current Deferred Tax Liability figures stand at $20.2 million (Q1 2026), $21.5 million (Q4 2025), and $18.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Ascend Wellness Holdings | 83.00 Mn | 22.91 Mn | 44.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.19 Mn |
| Mar 31, 2026 | 20.19 Mn |
| Dec 31, 2025 | 21.52 Mn |
| Dec 31, 2025 | 21.52 Mn |
| Sep 30, 2025 | 18.74 Mn |
| Sep 30, 2025 | 18.74 Mn |
| Jun 30, 2025 | 20.92 Mn |
| Jun 30, 2025 | 20.92 Mn |
| Mar 31, 2025 | 23.53 Mn |
| Mar 31, 2025 | 23.53 Mn |
| Dec 31, 2024 | 23.44 Mn |
| Dec 31, 2024 | 23.44 Mn |
| Sep 30, 2024 | 25.57 Mn |
| Sep 30, 2024 | 25.57 Mn |
| Jun 30, 2024 | 30.27 Mn |
| Jun 30, 2024 | 30.27 Mn |
| Mar 31, 2024 | 32.48 Mn |
| Mar 31, 2024 | 32.48 Mn |
| Dec 31, 2023 | 110.63 Mn |
| Dec 31, 2023 | 110.63 Mn |